Balvers RK - Search Results

1

Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial.

Bos EM, Binda E, Verploegh ISC, Wembacher E, Hoefnagel D, Balvers RK, Korporaal AL, Conidi A, Warnert EAH, Trivieri N, Visioli A, Zaccarini P, Caiola L, van Wijck R, van der Spek P, Huylebroeck D, Leenstra S, Lamfers MLM, Ram Z, Westphal M, Noske D, Legnani F, DiMeco F, Vescovi AL, Dirven CMF. Bos EM, et al. Among authors: balvers rk. Mol Cancer. 2023 Aug 10;22(1):129. doi: 10.1186/s12943-023-01835-6. Mol Cancer. 2023. PMID: 37563568 Free PMC article. Clinical Trial.

2

IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo.

Bralten LB, Kloosterhof NK, Balvers R, Sacchetti A, Lapre L, Lamfers M, Leenstra S, de Jonge H, Kros JM, Jansen EE, Struys EA, Jakobs C, Salomons GS, Diks SH, Peppelenbosch M, Kremer A, Hoogenraad CC, Smitt PA, French PJ. Bralten LB, et al. Ann Neurol. 2011 Mar;69(3):455-63. doi: 10.1002/ana.22390. Ann Neurol. 2011. PMID: 21446021

3

Laser speckle imaging identification of increases in cortical microcirculatory blood flow induced by motor activity during awake craniotomy.

Klijn E, Hulscher HC, Balvers RK, Holland WP, Bakker J, Vincent AJ, Dirven CM, Ince C. Klijn E, et al. Among authors: balvers rk. J Neurosurg. 2013 Feb;118(2):280-6. doi: 10.3171/2012.10.JNS1219. Epub 2012 Nov 23. J Neurosurg. 2013. PMID: 23176333 Clinical Trial.

4

Heterogeneous reovirus susceptibility in human glioblastoma stem-like cell cultures.

van den Hengel SK, Balvers RK, Dautzenberg IJ, van den Wollenberg DJ, Kloezeman JJ, Lamfers ML, Sillivis-Smit PA, Hoeben RC. van den Hengel SK, et al. Among authors: balvers rk. Cancer Gene Ther. 2013 Sep;20(9):507-13. doi: 10.1038/cgt.2013.47. Epub 2013 Aug 2. Cancer Gene Ther. 2013. PMID: 23907517

5

Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules.

Balvers RK, Kleijn A, Kloezeman JJ, French PJ, Kremer A, van den Bent MJ, Dirven CM, Leenstra S, Lamfers ML. Balvers RK, et al. Neuro Oncol. 2013 Dec;15(12):1684-95. doi: 10.1093/neuonc/not116. Epub 2013 Sep 17. Neuro Oncol. 2013. PMID: 24046260 Free PMC article.

6

Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma.

Balvers RK, Belcaid Z, van den Hengel SK, Kloezeman J, de Vrij J, Wakimoto H, Hoeben RC, Debets R, Leenstra S, Dirven C, Lamfers ML. Balvers RK, et al. Viruses. 2014 Aug 12;6(8):3080-96. doi: 10.3390/v6083080. Viruses. 2014. PMID: 25118638 Free PMC article.

7

ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.

Balvers RK, Lamfers ML, Kloezeman JJ, Kleijn A, Berghauser Pont LM, Dirven CM, Leenstra S. Balvers RK, et al. J Transl Med. 2015 Feb 26;13:74. doi: 10.1186/s12967-015-0427-y. J Transl Med. 2015. PMID: 25886061 Free PMC article.

8

In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells.

Berghauser Pont LM, Balvers RK, Kloezeman JJ, Nowicki MO, van den Bossche W, Kremer A, Wakimoto H, van den Hoogen BG, Leenstra S, Dirven CM, Chiocca EA, Lawler SE, Lamfers ML. Berghauser Pont LM, et al. Among authors: balvers rk. Gene Ther. 2015 Dec;22(12):947-59. doi: 10.1038/gt.2015.72. Epub 2015 Jul 21. Gene Ther. 2015. PMID: 26196249

9

A Systematic Comparison Identifies an ATP-Based Viability Assay as Most Suitable Read-Out for Drug Screening in Glioma Stem-Like Cells.

Kleijn A, Kloezeman JJ, Balvers RK, van der Kaaij M, Dirven CM, Leenstra S, Lamfers ML. Kleijn A, et al. Among authors: balvers rk. Stem Cells Int. 2016;2016:5623235. doi: 10.1155/2016/5623235. Epub 2016 May 5. Stem Cells Int. 2016. PMID: 27274737 Free PMC article.

10

Malignant Glioma In Vitro Models: On the Utilization of Stem-like Cells.

Balvers RK, Dirven CM, Leenstra S, Lamfers ML. Balvers RK, et al. Curr Cancer Drug Targets. 2017;17(3):255-266. doi: 10.2174/1568009616666160813191809. Curr Cancer Drug Targets. 2017. PMID: 27528360 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

21 results

Search Page